← Human Trials & Peer-Reviewed Studies
Preliminary validity of the modified Cigarette Evaluation Questionnaire in predicting the reinforcing effects of cigarettes that vary in nicotine content.
Plain-language guide to PMID 29251976 (2017): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 29251976
- Journal
- Experimental and clinical psychopharmacology
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Arger CA et al. (10 authors)
- DOI
- 10.1037/pha0000145
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).
Validity studies evaluating self-report measures in relation to behavioral preference of cigarettes varying in nicotine content are needed.
Data for this secondary analysis were obtained from a double-blind study (Higgins et al., 2017) evaluating the subjective and reinforcing effects of Spectrum cigarettes under acute smoking abstinence.
Who Took Part
By PubMed's age tags, the people studied were adults, both men and women.
Current smokers (N = 26) were recruited from three vulnerable smoking populations (economically disadvantaged women of reproductive age, opioid-maintained individuals, individuals with affective disorders).
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).
What Was Measured
Validity studies evaluating self-report measures in relation to behavioral preference of cigarettes varying in nicotine content are needed.
Data for this secondary analysis were obtained from a double-blind study (Higgins et al., 2017) evaluating the subjective and reinforcing effects of Spectrum cigarettes under acute smoking abstinence.
PubMed files the paper under topics including Nicotine, Nicotinic Agonists, Outcome Assessment, Health Care, Personal Satisfaction, Predictive Value of Tests, Reinforcement, Psychology and Reproducibility of Results.
What This Means in Plain Language
The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).
The publication is from 2017 (Experimental and clinical psychopharmacology), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.